USFDAJun 1, 2026, 07:02 AM
Elite Pharma Files ANDA for Generic Anticoagulant
AI Summary
Elite Pharmaceuticals, Inc. announced the submission of an Abbreviated New Drug Application (ANDA) to the U.S. FDA for a generic anticoagulant drug. The branded product had sales of $26 billion for the twelve months ending March 2026, with no generic competition currently on the market. Commercialization is contingent on FDA approval and addressing existing patents and exclusivities.
Key Highlights
- Elite Pharmaceuticals filed an Abbreviated New Drug Application (ANDA) with the US FDA.
- The ANDA is for a generic version of an undisclosed anticoagulant drug product.
- Branded product sales for the anticoagulant were $26 billion for the 12 months ending March 2026.
- There is currently no generic product on the market for this anticoagulant.
- Commercialization depends on FDA approval and addressing unexpired patents and exclusivities.
Price Impact
More from ELTP